IP Library Granted Patent US 9,035,122
Granted Patent B2
US 9,035,122 · App. 13/780,741 · Granted May 19, 2015

Wound dressing inhibiting lateral diffusion of absorbed exudate

Inventor: David A. Richard (Shingle Springs, CA)
Assignee: PolyRemedy, Inc.
A61F13/00042A61F13/00987A61F13/00029
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,035,122
App. No.
13/780,741
Granted
May 19, 2015
Kind
B2
Abstract

A wound dressing including a hydrophilic layer and a hydrophobic layer is described. The hydrophilic layer absorbs exudate from a wound and the hydrophobic layer absorbs the exudate from the hydrophilic layer and traps the exudate. Because the hydrophilic layer is used adjacent to the wound, the exudate is readily absorbed thereby reducing the risk of maceration and infection of the wound tissue by the exudate. The hydrophobic layer receives the absorbed exudate from the hydrophilic layer and traps the exudate through an interaction that in turn prevents lateral diffusion of the exudate through the bandage to healthy portions of the skin. The hydrophilic and hydrophobic layers are fabricated from polymer fibers that can be spun to include components that facilitate wound healing, such as poly(hexamethylene biguanide) and/or hyaluronic acid.

Claims (28)

1. A wound dressing comprising:

a proximal hydrophilic layer fabricated from a first fibrous polymer including fibers that comprise at least one polymer and hyaluronic acid, the first fibrous polymer configured for placement adjacent to a portion of skin producing exudate to absorb the exudate; and

a hydrophobic layer in contact with the proximal hydrophilic layer, the hydrophobic layer comprising a second fibrous polymer configured for receiving the exudate absorbed by the proximal hydrophilic layer and storing the exudate at inter-fiber gaps to inhibit lateral diffusion of the exudate in the wound dressing.

2. The wound dressing of claim 1 , wherein the second fibrous polymer of the hydrophobic layer undergoes a volume reduction upon storing the exudate at interstitial gaps.

3. The wound dressing of claim 1 , wherein the first fibrous polymer of the proximal hydrophilic layer comprises fibers of poly(ethylene oxide) and poly(ethylene-co-vinyl alcohol),the fibers having an average diameter of about 180 nm to about 400nm.

4. The wound dressing of claim 3 , wherein the first fibrous polymer of the proximal hydrophilic layer further comprises poly(hexamethylene biguanide) in the fibers of poly(ethylene-co-vinyl alcohol).

5. The wound dressing of claim 1 , wherein the first fibrous polymer of the proximal hydrophilic layer comprises fibers of poly(ethylene oxide) and poly(ethylene-co-vinyl alcohol),the fibers having an interstitial gap size of between 1 micron and 2.5microns.

6. The wound dressing of claim 1 , wherein the second fibrous polymer of the hydrophobic layer comprises fibers of poly(caprolactol), the fibers having an average diameter of about 180 nm to about 400 nm.

7. The wound dressing of claim 6 , wherein the second fibrous polymer of the hydrophobic layer further comprises fibers of poly(ethylene-co-vinyl alcohol) mixed with the fibers of poly(caprolactol).

8. The wound dressing of claim 1 , wherein the second fibrous polymer of the hydrophobic layer comprises fibers of poly(caprolactol), the fibers having an interstitial gap size of between 1 micron and 2.5 microns.

9. The wound dressing of claim 1 , wherein the second fibrous polymer of the hydrophobic layer further comprises poly(hexamethylene biguanide hydrochloride) in the fibers of poly(caprolactol).

10. The wound dressing of claim 1 , further comprising a distal hydrophilic layer in contact with the hydrophobic layer and opposite the proximal hydrophilic layer, the distal hydrophilic layer facilitating evaporation of liquid in the exudate from the wound dressing.

11. The wound dressing of claim 1 , wherein the hydrophobic layer includes at least a first and a second hydrophobic sub-layers, the first hydrophobic sub-layer comprising fibers of poly(caprolactol) that include hyaluronic acid, sodium chloride, and a tri-block copolymer of poly(ethylene glycol) and polypropylene glycol), and the second hydrophobic sub-layer comprising fibers poly(ethylene oxide) and poly(caprolactol).

12. The wound dressing of claim 1 , wherein the fibers of the first fibrous polymer are configured to release hyaluronic acid as exudate is absorbed.

13. A wound dressing comprising:

a proximal hydrophilic layer fabricated from a fibrous polymer and configured for placement adjacent to a portion of skin producing exudate to absorb the exudate; and

a fibrous hydrophobic layer in contact with the proximal hydrophilic layer, the fibrous hydrophobic layer configured to receive the exudate absorbed by the proximal hydrophilic layer and store the exudate at inter-fiber gaps to inhibit lateral diffusion of the exudate in the wound dressing, the fibrous hydrophobic layer comprising:

a first hydrophobic sub-layer comprising fibers of poly(caprolactol) that include hyaluronic acid, sodium chloride, and a tri-block copolymer of poly(ethylene glycol) and polypropylene glycol); and

a second hydrophobic sub-layer comprising fibers poly(ethylene oxide) and poly(caprolactol).

14. The wound dressing of claim 13 , wherein a volume of the fibrous hydrophobic layer is reduced as the exudate is stored at interstitial gaps of the fibrous hydrophobic layer.

15. The wound dressing of claim 13 , wherein the fibers of poly(caprolactol) of the first hydrophobic sub-layer further comprise poly(hexamethylene biguanide hydrochloride) in the fibers of poly(caprolactol).

16. The wound dressing of claim 13 , wherein the fibers of poly(caprolactol) of the first hydrophobic sub-layer have an interstitial gap size of between 1 micron and 2.5 microns.

17. The wound dressing of claim 13 , wherein the proximal hydrophilic layer comprises fibers of poly(ethylene oxide) and poly(ethylene-co-vinyl alcohol), the fibers having an interstitial gap size of between 1 micron and 2.5 microns.

18. The wound dressing of claim 13 wherein the fibrous polymer of the proximal hydrophilic layer comprises poly(hexamethylene biguanide) in fibers of poly(ethylene-co-vinyl alcohol).

19. The wound dressing of claim 13 , further comprising a distal hydrophilic layer in contact with the fibrous hydrophobic layer and locate opposite to the proximal hydrophilic layer, the distal hydrophilic layer configured to facilitate evaporation of liquid in the exudate from the wound dressing.

20. A wound dressing comprising:

a proximal hydrophilic layer fabricated from a first fibrous polymer and configured for placement adjacent to a portion of skin producing exudate to absorb the exudate; and

a hydrophobic layer in contact with the proximal hydrophilic layer, the hydrophobic layer comprising a second fibrous polymer of poly(caprolactol) having a plurality of interstitial gaps, each interstitial gap having a size of between 1 micron and 2.5microns, the second fibrous polymer configured for receiving the exudate absorbed by the proximal hydrophilic layer and storing the exudate at the plurality of interstitial gaps to inhibit lateral diffusion of the exudate in the wound dressing.

Assignments (7)
FLORIDA ARTICLES OF INCORPORATION Recorded Nov 29, 2017
From: NUVESSE SKIN THERAPIES, INC.
To: NUVESSE SKIN THERAPIES, INC.
Reel/Frame 044551/0522 →
CERTIFICATE OF CONVERSION Recorded Nov 29, 2017
From: POLYREMEDY, INC.
To: NUVESSE SKIN THERAPIES, INC.
Reel/Frame 044551/0512 →
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2016
From: ADVANCED TECHNOLOGY VENTURES VIII, L.P.; FLYBRIDGE CAPITAL PARTNERS II, L.P.; MEDVENTURE ASSOCIATES V, L.P.; MICHAEL MURRAY TRADING PARTNERS, L.P.; BARRETT, KEVIN
To: NUVESSE SKIN THERAPIES, INC.
Reel/Frame 040024/0139 →
CHANGE OF NAME Recorded Oct 7, 2016
From: POLYREMEDY, INC.
To: NUVESSE SKIN THERAPIES, INC.
Reel/Frame 039969/0276 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS OF ASSIGNEE: KEVIN BARRETT PREVIOUSLY RECORDED ON REEL 038832 FRAME 0047. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST. Recorded Jun 8, 2016
From: POLYREMEDY, INC.
To: ADVANCED TECHNOLOGY VENTURES VIII, L.P.; FLYBRIDGE CAPITAL PARTNERS II, L.P.; MEDVENTURE ASSOCIATES V, L.P.; KEVIN BARRETT; MICHAEL MURRAY TRADING PARTNERS, L.P.
Reel/Frame 038925/0748 →
SECURITY AGREEMENT Recorded May 27, 2016
From: POLYREMEDY, INC.
To: ADVANCED TECHNOLOGY VENTURES VIII, L.P.; FLYBRIDGE CAPITAL PARTNERS II, L.P.; MEDVENTURE ASSOCIATES V, L.P.; BARRETT, KEVIN; MICHAEL MURRAY TRADING PARTNERS, L.P.
Reel/Frame 038832/0047 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2013
From: RICHARD, DAVID A.
To: POLYREMEDY, INC.
Reel/Frame 030315/0201 →
Continuity (2)
Provisional Application 61606911 · Mar 5, 2012
Related Publication 20130231623A1 · Sep 5, 2013